Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The Wild West of Checkpoint Inhibitor Development.

Literature DB >> 34910860

The Wild West of Checkpoint Inhibitor Development.

Julia A Beaver¹, Richard Pazdur¹.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2021 PMID： 34910860 DOI： 10.1056/NEJMp2116863

Source DB: PubMed Journal: N Engl J Med ISSN： 0028-4793 Impact factor: 91.245

Keyword Cloud
Cited

× No keyword cloud information.

11 in total

1. Encouraging Rigorous Patient-Generated Data All Along the Drug Development Continuum.

Authors: Vishal Bhatnagar; Paul G Kluetz
Journal: J Natl Cancer Inst Date: 2022-10-06 Impact factor: 11.816

2. The role of immune checkpoint inhibitors in clinical practice: an analysis of the treatment patterns, survival and toxicity rates by sex.

Authors: Murielle N Wahli; Stefanie Hayoz; Dennis Hoch; Christoph O Ryser; Michèle Hoffmann; Amina Scherz; Birgit Schwacha-Eipper; Simon Häfliger; Julian Wampfler; Martin D Berger; Urban Novak; Berna C Özdemir
Journal: J Cancer Res Clin Oncol Date: 2022-08-23 Impact factor: 4.322

3. Imaging response assessment for oncology: An algorithmic approach.

Authors: Kathleen Ruchalski; Rohit Dewan; Victor Sai; Lacey J McIntosh; Marta Braschi-Amirfarzan
Journal: Eur J Radiol Open Date: 2022-06-07

4. A Proposal to Increase Value and Equity in the Development and Distribution of New Pharmaceuticals.

Authors: Paul Sorum; Christopher Stein; Danielle Wales; David Pratt
Journal: Int J Health Serv Date: 2022-05-12 Impact factor: 1.851

5. Clinical trials for metastatic castrate-resistant prostate cancer-who is looking after the control patients? Questions for the future.

Authors: L C Ardolino; R Dear; A J Armstrong; S Gillessen; A M Joshua
Journal: Ann Oncol Date: 2022-03-29 Impact factor: 51.769

The Wild West of Checkpoint Inhibitor Development.

1. Encouraging Rigorous Patient-Generated Data All Along the Drug Development Continuum.

2. The role of immune checkpoint inhibitors in clinical practice: an analysis of the treatment patterns, survival and toxicity rates by sex.

3. Imaging response assessment for oncology: An algorithmic approach.

4. A Proposal to Increase Value and Equity in the Development and Distribution of New Pharmaceuticals.

5. Clinical trials for metastatic castrate-resistant prostate cancer-who is looking after the control patients? Questions for the future.

Review 6. Immune Related Adverse Events of the Thyroid - A Narrative Review.

7. Approvals in 2021: dangling Accelerated Approvals, drug dosing, new approvals and beyond.

Review 8. Availability and Affordability of Oncology Drugs in 2012-2021 in China and the United States.

Review 9. Emerging Novel Combined CAR-T Cell Therapies.

10. Insights for Oncology Trials Garnered From the Rapid Development of an mRNA COVID-19 Vaccine.